Competing event risk stratification may improve the design and efficiency of clinical trials: Secondary analysis of SWOG 8794

Contemporary Clinical Trials

Volumn 34, Issue 1, 2013, Pages 74-79

  Zakeri, Kaveh ^a   Rose, Brent S ^b   Gulaya, Sachin ^a   D'Amico, Anthony V ^c   Mell, Loren K ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Competing mortality; Competing risks; Prostate cancer; Radiation therapy

Indexed keywords

AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL (TOPIC); DEATH; EVENT FREE SURVIVAL; HIGH RISK PATIENT; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; METASTASIS; MORTALITY; OVERALL SURVIVAL; PROSTATE CANCER; RISK ASSESSMENT; SCORING SYSTEM; STRATIFICATION;

CAUSE OF DEATH; CLINICAL TRIALS AS TOPIC; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; HUMANS; MALE; PROSTATIC NEOPLASMS; RISK ASSESSMENT; SURVIVAL RATE; UNITED STATES;

EID: 84870545283     PISSN: 15517144     EISSN: 15592030     Source Type: Journal    
DOI: 10.1016/j.cct.2012.09.008     Document Type: Article

References (18)

1. Punt C.J., Buyse M., Kohne C.H., Hohenberger P., Labianca P., Schmoll H.J., et al. Endpoints in adjuvant treatment trials: a systematic review of the literature in colon cancer and proposed definitions for future trials. J Natl Cancer Inst 2007, 99:998-1003.
2. Hudis C.A., Barlow W.E., Costantino J.P., Gray R.J., Pritchard K.I., Chapman J.A., et al. Proposal for standardized definitions for efficacy end points in adjuvant breast cancer trials: the STEEP system. J Clin Oncol 2007, 25:2127-2132.
3. Mell L.K., Jeong J.H. Pitfalls of using composite primary end points in the presence of competing risks. J Clin Oncol 2010, 28:4297-4299.
4. Dignam J.J., Kocherginsky M.N. Choice and interpretation of statistical tests used when competing risks are present. J Clin Oncol 2008, 26:4027-4034.
5. Latouche A., Porcher R. Sample size calculations in the presence of competing risks. Stat Med 2007, 26:5370-5380.
6. Mell L.K., Weichselbaum R.R. More on cetuximab in head and neck cancer. N Engl J Med 2007, 357:2201-2202.
7. Freemantle N., Calvert M., Wood J., Eastaugh J., Griffin C. Composite outcomes in randomized trials: greater precision but with greater uncertainty?. JAMA 2003, 289:2554-2559.
8. Thompson I.M., Tangen C.M., Paradelo J., Lucia M.S., Miller G., Troyer D., et al. Adjuvant radiotherapy for pathologically advanced prostate cancer: a randomized clinical trial. JAMA 2006, 296:2329-2335.
9. Thompson I.M., Tangen C.M., Paradelo J., Lucia M.S., Miller G., Troyer D., et al. Adjuvant radiotherapy for pathological T3N0M0 prostate cancer significantly reduces risk of metastases and improves survival: long-term followup of a randomized clinical trial. J Urol 2009, 181:956-962.
10. Korn E.L., Dorey F.J. Applications of crude incidence curves. Stat Med 1992, 11:813-829.
11. Gaynor J.J., Feuer E.J., Tan C.C., Wu D.H., Little C.R., Straus D.J., et al. On the use of cause-specific failure and conditional failure probabilities: examples from clinical oncology data. J Am Stat Assoc 1993, 88:400-409.
12. Cox D.R. Regression models and life tables. J R Stat Soc Series B Stat Methodol 1972, B34:187-220.
13. Fine J.P., Gray R.J. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 1999, 94:496-509.
14. Charlson M.E., Pompei P., Ales H.L. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987, 40:373-383.
15. Prentice R.L., Kalbfleisch J.D., Peterson A.V., Flournoy N., Farewell V.T., Breslow N.E. The analysis of failure times in the presence of competing risks. Biometrics 1978, 34:541-554.
16. Dignam J.J., Zhang Q., Kocherginsky M. The use and interpretation of competing risks regression models. Clin Cancer Res 2012, 18:2301-2308.
17. Pintilie M. Dealing with competing risks: testing covariates and calculating sample size. Stat Med 2002, 21:3317-3324.
18. Rose B.S., Jeong J.H., Nath S.K., Lu S.M., Mell L.K. Population-based study of competing mortality in head and neck cancer. J Clin Oncol 2011, 29:3503-3509.